This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): cidofovir
Description: Vistide targets viral DNA polymerase and prevents transcription. Because the viral polymerase is 8 to 600 times more sensitive than human DNA alpha, beta, and gamma polymerases, the active ingredient, cidofovir diphosphate, is able to specifically target viral replication processes. It must be administered in conjunction with prodenecid in order to block renal tubular secretion of cidofovir.
Deal Structure: In August 1996, Gilead and Pharmacia & Upjohn (now Pfizer) entered into a collaboration whereby Pharmacia was given exclusive rights to market VISTIDE (cidofovir injection) for the treatment of cytomegalovirus retinitis in patients with HIV in all countries outside of the United States. Under the terms of the agreement, Pharmacia paid Gilead a $10 million initial license fee, and an additional $10 million milestone payment upon receipt of the European Marketing Authorisation for VISTIDE in May 1997. Pfizer also pays Gilead royalty payments on sales of VISTIDE. In addition, as a result of receiving the European Marketing Authorisation, Pharmacia purchased 1,133,786 shares of newly issued Series B Convertible Preferred Stock for approximately $40 million or $35.28 per share. Pfizer is now marketing VISTIDE in the United Kingdom, Australia, Spain, Ireland, Switzerland, France, Germany, Hungary, Austria, Sweden, Denmark, Italy, Netherlands, Portugal, Hong Kong, Belgium, Finland and...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Pink Sheet In Brief: Gilead Sciences' Vistide
Additional information available to subscribers only: